Canada, like many countries, is facing escalating health care costs as payers struggle to reconcile finite drug budgets with patient access to promising new health technologies. Improving affordability and access to prescription drugs is a key Government of Canada commitment and a joint federal, provincial, and territorial priority.
As a first step to framework modernization, the Patented Medicine Prices Review Board (PMPRB) is undertaking major consultations regarding possible reform of its Compendium of Policies, Guidelines and Procedures, commonly referred to as “the Guidelines.”
During Phase 1 of this consultation initiative, the PMPRB asked for your input on how we can rethink the Guidelines in order to improve our performance in ensuring that pharmaceutical patent holders do not charge excessive prices. We are now analyzing the feedback we received. The PMPRB Guidelines Modernization Discussion Paper and discussion questions are still available online for those who wish to consult them.
Phase 2 of the consultation process is expected to consist of a public policy hearing before the Board, where stakeholders who commented on the Discussion Paper will have the opportunity to speak to their written submissions. Timelines for Phase 2 will be announced at a later date.
By Rethinking the Guidelines, the PMPRB seeks to contribute to a sustainable pharmaceutical system where payers have the information they need to make smart reimbursement choices and Canadians can afford the medicines they need to live healthy and productive lives.
Phase 1 is now complete; and the list of submissions can be found by clicking here.
You can also see the submission of the Canadian Cancer Survivor Network, which participated in a coalition of concerned patient groups, by clicking here.